ESGO 2017 Vienna Congress

 

>> Parallel Session: PHASE I / II TRIALS: THE ENGOT STRATEGY

Chairs: Nicole Concin and Ignace Vergote

 

• ENGOT Phase I /II trials: introduction of the new group

Nicole Concin, Austria  

• A new concept of Umbrella Phase I/II trials

Mansoor Raza Mirza, Denmark

• Future directions of interesting compounds for early clinical testing

Antonio Casado, Spain

 

The session introduced the new early clinical trial group of ENGOT, including information on group composition, goals, concept, trial selection, failures and achievements.

The concept of Umbrella Phase I/II was explained and realised ongoing trials by the group were reviewed.

The session also gave a future perspective on interesting drugs and treatment strategies about to enter early clinical testing.

 

>> Parallel Session: PLATINUM RESISTANCE - A CHALLENGE IN OVARIAN CANCER TREATMENT

Chairs: Mansoor Mirza, Denmark and Nicole Concin, Austria

 

• Platinum-resistant disease: Current status –

Nicole Concin, Austria

• Strategies for overcoming resistance to chemotherapy

Sandro Pignata, Italy

• Clinical Trials in platinum-resistant disease –

Mansoor Raza Mirza, Denmark

 

The session gave an overview on the clinical area of platinum-resistant ovarian cancer, briefly mentioning definition, summarising current standard treatment options and outcomes.

Newest literature was reviewed regarding underlying mechanisms of resistance and strategies to overcome resistance.

Clinical application of promising mechanism to overcome resistance currently being tested in clinical trials was reviewed.

The session also gave an outlook and future perspective on this topic.

 

>> Parallel Session: CURRENT STATUS OF IMMUNOTHERAPY

Chairs: Jonathan Ledermann and Christian Marth

• Principles of immunotherapy.

Christian Marth, Austria

• Challenges of immunotherapy: predictive factors and response criteria.

Francis Balkwill, UK

• Ovarian cancer immunotherapy trials:

Jonathan Ledermann, UK

• Cervical cancer immunotherapy trial

 

Immunotherapeutics is the fastest growing area of cancer treatment. Studies are underway to evaluate new drugs that alter the host immune environment stimulating immune therapy of gynaecological cancers.

The session covered the basic principles underlying immunotherapy, the host factors influencing the immune response to cancer as well as the results of trials and ongoing studies evaluating new immunotherapeutics in gynaecological cancers.

 

>> Parallel Session: NEW END POINTS TO ASSESS THE IMPACT OF TREATMENT AND RELATED MORBIDITY ON OUTCOME

Chairs: Remi Nout and Lonneke van de Poll-Franse

 

• ‘Overview of current developments in measuring and reporting patient reported outcomes and quality of life in GYNAECOLOGICal cancer’. 

van der Poll – Franse, The Netherlands

• ‘How to integrate patient reported outcome tools in the everyday GYNAECOLOGICal cancer clinic’. 

Galina Velikova  UK

• ‘Which role can patient reported outcomes and quality of life have in clinical trials’? 

Nout, The Netherlands

 

This session provided an overview of current developments in measuring and reporting patient reported outcomes (PRO) and quality of life (QoL) in GYNAECOLOGICal cancer.

Thereby focusing on the questions how to integrate PRO tools in the everyday clinic, and which role PRO and QoL can have in clinical trials.